ACCESS Newswire·Dec 11, 2025, 5:00 PM ET

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

XBIO

Xenetic Biosciences Inc. adjourned its 2025 Annual Meeting of Stockholders without conducting business due to a lack of quorum.
Fewer than a majority of outstanding shares entitled to vote were present in person or by proxy at the initial meeting.
The Annual Meeting will reconvene virtually at 10:00 a.m. Eastern Time on Thursday, January 8, 2026.
Stockholders who already submitted proxies or votes do not need to vote again as prior submissions remain valid unless revoked.
The record date for determining voting eligibility at the reconvened meeting remains October 15, 2025.
Stockholders who have not yet voted are urged to vote online at www.proxyvote.com or by telephone before 11:59 p.m. Eastern Time on January 7, 2026.
Shares held in brokerage accounts may be subject to earlier voting deadlines per the holding organization's instructions.
The definitive proxy statement is available on www.proxyvote.com, www.xeneticbio.com, or via the SEC website.
The reconvened meeting will be accessible virtually at http://www.virtualshareholdermeeting.com/XBIO2025 for eligible stockholders.
Stockholder questions can be directed to Okapi Partners LLC at 877-629-6355.
Xenetic Biosciences is a biopharmaceutical company advancing immuno-oncology technologies, including a DNase program targeting neutrophil extracellular traps for pancreatic carcinoma & solid tumors.
The press release includes forward-looking statements regarding the DNase platform, potential strategic alternatives, & various risks that could affect actual results.